Effects of acepromazine and xylazine on subjective and objective assessments of forelimb lameness.
Authors: Morgan Jessica M, Ross Michael W, Levine David G, Stefanovski Darko, You Youwen, Robinson Mary A, Davidson Elizabeth J
Journal: Equine veterinary journal
Summary
# Editorial Summary: Sedation and Lameness Assessment in Horses Low-dose sedation with xylazine (0.1–0.2 mg/kg IV) or acepromazine (0.02–0.04 mg/kg IV) does not mask forelimb lameness signs during clinical evaluation, addressing a longstanding concern amongst equine practitioners who use these agents to facilitate examination. Six horses with experimentally induced solar pain were assessed using both objective measures (inertial sensors measuring vector sum displacement) and subjective grading (0–5 scale) across multiple timepoints following sedation, local analgesia, or saline control in a randomised, blinded crossover design. Neither sedative significantly altered objective or subjective lameness assessments over the 1-hour evaluation period, whereas local analgesia (2% mepivacaine) predictably reduced both subjective grades and objective vector sum values by 45 minutes post-administration. Practitioners can confidently use these low doses of xylazine or acepromazine to improve horse compliance during lameness examinations without concern that the medications will obscure the underlying pathology, though caution should be exercised when extrapolating findings from experimentally induced, moderate-intensity solar pain to the broader spectrum of clinical lameness presentations.
Read the full abstract on PubMed
Practical Takeaways
- •Low doses of xylazine or acepromazine can be safely used during lameness examinations for up to 1 hour without masking moderate forelimb lameness signs
- •These sedatives improve horse compliance during evaluation without artificially improving or worsening observed lameness grades, supporting their routine clinical use
- •Local analgesia will reduce apparent lameness, so intra-articular or regional blocks must be withheld until after baseline lameness assessment if diagnostic blocking is not the intended outcome
Key Findings
- •Low-dose xylazine (0.1–0.2 mg/kg IV) did not significantly affect objective or subjective lameness assessment over 1 hour
- •Low-dose acepromazine (0.02–0.04 mg/kg IV) did not significantly affect objective or subjective lameness assessment over 1 hour
- •Local analgesia (2% mepivacaine) significantly decreased subjective lameness grade (OR 0.32, P=0.03) and objective lameness measures at 45 and 60 minutes post-administration
- •Results support the use of low-dose sedatives to facilitate forelimb lameness evaluation in clinical settings without confounding assessment